• University of Cambridge Featured PhD Programmes
  • Aberdeen University Featured PhD Programmes
  • University of Tasmania Featured PhD Programmes
  • University of Pennsylvania Featured PhD Programmes
  • Staffordshire University Featured PhD Programmes
University of Tasmania Featured PhD Programmes
Peter MacCallum Cancer Centre Featured PhD Programmes
EPSRC Featured PhD Programmes
Coventry University Featured PhD Programmes
University of Reading Featured PhD Programmes

Validating diagnostic and prognostic marker for T cell Leukaemias (HLS/SE/DRFAPP7P/63604)

This project is no longer listed in the FindAPhD
database and may not be available.

Click here to search the FindAPhD database
for PhD studentship opportunities
  • Full or part time
    Dr Soundararajan
  • Application Deadline
    Applications accepted all year round

Project Description

This project specifically focusses on validating human Trib2, which belongs to the popular class of protein kinases as a drug target for specific T cell Leukaemias.

Human Tribbles-2 (Trib-2) belong to Tribbles proteins (trb-1, trb-2 and trb-3) which are potent negative regulators of MAPK pathways and core transcriptional regulatory circuits influencing apoptosis, differentiation and cell-cycle progression. Initial studies show Trib-2 tumour suppressor activity is abrogated in a proportion of acute myeloid leukaemia (AML) T cell acute lymphoblastic leukaemia patients. Here we aim to examine the tribble gene’s expression in specific cancer types including AML. The work will focus on elucidating the role of Trib2 in cell survival and pathogenesis of leukaemic subtypes using cell biology and structural Biochemistry work to characterise their molecular role in leukaemic cells. Analysing and validating the target will also include functional genomics and proteomics approaches during this study. Successful completion of this work aims to validate a novel Trib class protein kinase as a therapeutic target for treatment of myeloid leukaemias and specific adenocarcinomas. Further, chemical biology approaches to identify Trib2 chemical inhibitors will be carried out to develop lead therapeutic compounds to tackle T cell myeloid leukaemias.

Informal Enquiries
Enquiries regarding this studentship should be made to: title name & email address
Dr Meera Soundararajan - [email protected]
For further details of how to apply, entry requirements and the application form, see
https://www.northumbria.ac.uk/research/postgraduate-research-degrees/how-to-apply/
Please ensure you quote the advert reference above on your application form.

Eligibility
For further details of how to apply, entry requirements and the application form, see
https://www.northumbria.ac.uk/research/postgraduate-research-degrees/how-to-apply/
Please ensure you quote the advert reference above on your application form.

How to Apply
For further details of how to apply, entry requirements and the application form, see
https://www.northumbria.ac.uk/research/postgraduate-research-degrees/how-to-apply/
Please ensure you quote the advert reference above on your application form.

Funding Notes

This studentship is only open to self-funding candidates. Self-funding candidates are expected to pay University fees and to provide their own living costs. In addition, a ‘bench fee’ will have to be paid to cover project running costs (at a level that will be determined specifically for each project).

References

Eswaran J, Soundararajan M, Knapp S. Targeting group II PAKs in cancer and metastasis. Cancer Metastasis Rev. 2009 Jun;28(1-2):209-17. Review.
Kwiatkowski N, Jelluma N, Filippakopoulos P, Soundararajan M, Manak MS, Kwon M, Choi HG, Sim T, Deveraux QL, Rottmann S, Pellman D, Shah JV, Kops GJ, Knapp S, Gray NS. Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function. Nat Chem Biol. 2010 May;6(5):359-68.

Share this page:

Cookie Policy    X